Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges, World Journal of Biological Chemistry, vol.3, issue.4, pp.73-92, 2012. ,
DOI : 10.4331/wjbc.v3.i4.73
Early Development of Therapeutic Biologics - Pharmacokinetics, Current Drug Metabolism, vol.7, issue.1, pp.15-21, 2006. ,
DOI : 10.2174/138920006774832604
Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration, Pharmaceutical Research, vol.07, issue.2, pp.167-176, 1990. ,
DOI : 10.1023/A:1015880819328
Clinical pharmacology considerations in biologics development, Acta Pharmacologica Sinica, vol.87, issue.11, pp.1339-1347 ,
DOI : 10.1038/aps.2012.51
ADME of biologics-What Have We Learned from Small Molecules ?; The AAPS Journal, pp.410-41905, 2012. ,
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues EMA, 2010. ,
Biosimilars require scientifically reliable comparative clinical data, Revista Brasileira de Reumatologia (English Edition), vol.53, issue.1 ,
DOI : 10.1016/S2255-5021(13)70013-0
System Pharmacist's Guide to Biosimilars: Regulatory, Scientific, and Practical Considerations ; Disponible sur http ,
Les copies du Lovenox sont elles à considérer comme des génériques ou des biosimilaires ? ; Société Algérienne de Médecine Vasculaire 2009 disponible sur http ,
Leem : les entreprises du médicament ; Septembre2013, Etat des lieux, 2014. ,
Démystifier les médicaments biosimilaires : Guide à l'intention des rédacteurs scientifiques ; Disponible sur http ,
disponible sur http://ansm.sante.fr/S-informer/Actualite/Abasria-insuline-glargine- Clopidogrel-ASATeva-Daklinza-daclastavir-Velphoro-Vizamyl-flutemetamol- f-18-Triumeq-abacavir-dolutegravir-lamivudine-retour-sur-la-reunion-de-juin- 2014-du-CHMP-Point-d-information consulté le 02, Juin, vol.08, 2014. ,
Génétiques les grands principes 3eme Ed. ; Dunod ; Sciences Sup, 2003. ,
Comparability of biotechnological/biological products subject to change in their manufacturing process IMS Health, analyse développement & Conseil, 2008. ,
Assays Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization profiles of Generics Copies of Enoxaparin, Blood (ASH Annual Meeting Abstracts) 2006 108 Poster Board #-Session, p.36 ,
Comparability Studies : The Keys to a Biosimilar's Success ; Biopharmaceutical Solution ; Covance Webinar ,
le-lovenox-de-sanofi-generique-aux-etats- unis, pp.28-35 ,
Les biosimilaires en 15 questions Disponible sur http://www.apmnews.com/Documents/lesbiosimilairesen15questionsemail, Avril, vol.08, 2014. ,
Challenges in early clinical development of biologics : Mars 2011 ; disponible sur http, 2014. ,
Copies des médicaments issus de biotechnlogies (« biosimialire ») : l'agence européenne évolue timidement vers plus de pragmatisme ; Réponse conjointe à la consultation de l'EMA ; 31 Octobre 2013 disponible sur http, 2014. ,
Des médicaments issus des biotechnologies aux médicaments biosimilaires: Etat des lieux, Ansm.sante.fr consulté le 28, 2011. ,
Médicaments biosimilaires : Etat des lieux, 2013. ,
Bilan 2012 sur l'utilisation des biosimilaires : un équivalent du biomédicament de référence ou un générique biologique ?, Th D Pharm, 2012. ,
The impact of biosimilars's entry in the EU market ; Eminet, Janvier, 2011. ,
Disponible sur http://www.sanofi.com/Images/14182_080515-2_LOVENOX_USA_pdf, pp.28-35, 2008. ,
L'impact sur les thérapies et sur l'industrie pharmaceutique disponible sur http ,
The Challenges of Demonstrating Comparability of Biosimilar Products ; Bio Process Technology Consultants, Bioprocess Theater, 2010. ,
Leem : les entreprises du médicament ; Septembre2013, Etat des lieux, 2013. ,
Leem : les entreprises du médicament, Etat des lieux Avril, vol.http, 2011. ,
Developing Oncology Biosimilars : An Essential Approach for the future ; seminars in Oncology, Decembre Supp, vol.40, issue.1, pp.5-24, 2013. ,
Statistical consideration in the design of biosimilar cancer clinical trials ; National Institute of Health Korea, pp.495-503, 2011. ,
Biosimilars require scientifically reliable comparative clinical data, Revista Brasileira de Reumatologia (English Edition), vol.53, issue.1, pp.127-131 ,
DOI : 10.1016/S2255-5021(13)70013-0
Use of pharmacokinetics/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics, British Journal Of Clinical Pharmacology, vol.67, issue.2, pp.153-160, 2008. ,
Immunogenicity of protein therapeutics: The key causes, consequences and challenges, Self/Nonself, vol.1, issue.4, pp.314-322, 2010. ,
DOI : 10.4161/self.1.4.13904
Early Development of Therapeutic Biologics - Pharmacokinetics, Current Drug Metabolism, vol.7, issue.1, pp.15-21, 2006. ,
DOI : 10.2174/138920006774832604
Clinical programs in the development of similar biotherapeutic products: Rationale and general principles, Biologicals, vol.39, issue.5, pp.293-296, 2011. ,
DOI : 10.1016/j.biologicals.2011.06.024
Pure Red-Cell Aplasia and Epoetin Therapy, New England Journal of Medicine, vol.351, issue.14, pp.1403-1408, 2004. ,
DOI : 10.1056/NEJMoa040528
L'arrivée des anticorps changera-t-elle la donne ? ; Le pharmacien hôpital, Janvier, p.171, 2011. ,
Biosimilars: an overview, Mars, pp.1-5, 2011. ,
Innovation and competition: will biosimilars succeed, BiotechnolHealthc, vol.9, pp.24-31, 2012. ,
Biosimiliar regulation : Important consideration and global developments ; Cross Border Life Sciences Handbook, 2011. ,
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes, Kidney International, vol.67, issue.6, pp.2346-2353, 2005. ,
DOI : 10.1111/j.1523-1755.2005.00340.x
Cytokine-Release Syndrome: Overview and Nursing Implications, Clinical Journal of Oncology Nursing, vol.11, issue.0, pp.42-47, 2007. ,
DOI : 10.1188/07.CJON.S1.37-42
The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products ; Drug research, pp.641-648, 2008. ,
Developing Clinical Trials for Biosimilars ; Seminars in Oncology, FévrierS1, vol.41, pp.15-25, 2014. ,
Expert perspectives on biosimilar monoclonal antibodies in breast cancer, Breast Cancer Research and Treatment, vol.86, issue.2, pp.233-239, 2014. ,
DOI : 10.1007/s10549-014-2879-9
Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen??, BMC Pharmacology and Toxicology, vol.164, issue.5, p.7, 2014. ,
DOI : 10.1016/j.jconrel.2012.06.026
Pharmaceutical evaluation of biosimilars : important differences from generic low-molecular-weight pharmaceuticals, The European Journal of Hospital Pharmacy Science, vol.11, issue.1, pp.11-17, 2005. ,
Immunogenicity of protein therapeutics ; Trends Immunolo, pp.10-1016, 2007. ,
Similar biotherapeutic products: overview and reflections, Immunotherapy, vol.4, issue.12, pp.1841-1857, 2012. ,
DOI : 10.2217/imt.12.128
Produits biologiques et biosimilaires : science et implications, J Pharm Clin, vol.2013, issue.321, pp.17-22 ,
Clinical trial design in biosimilar drug development, Investigational New Drugs, vol.295, issue.337, pp.479-487, 2013. ,
DOI : 10.1007/s10637-012-9899-2
Glucose clamp technique: a method for quantifying Insulin secretion and resistance, Am J Physiol, vol.237, pp.214-223, 1979. ,
P ; The founding father of biotechnology: Károly (Karl) Ereky, International Journal of Horticultural Science, vol.2006, issue.121, pp.9-12 ,
Biosimilars clinical development program: Confirmatory clinical trials: A virtual/simulated case study comparing equivalence and non-inferiority approaches, Biologicals, vol.39, issue.5, pp.270-277, 2011. ,
DOI : 10.1016/j.biologicals.2011.06.004
Litjens V. ; L'érythroblastopénie induite par les érythropoïétines recombinantes ; Pharmactuel, pp.136-145, 2003. ,
Clinical experience with ZARZIO® in Europe : what have we learned ? ; Support Care Cancer, pp.2925-2932, 2013. ,
Development of a new G-CSF product based on biosimilarity assessment ; Annals of oncology, pp.1419-1429, 2010. ,
Presently available biosimilars in hematology-oncology: G-CSF, Targeted Oncology, vol.10, issue.7, pp.29-34 ,
DOI : 10.1007/s11523-011-0190-9
Mourão P ; Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: Similarity to the original drug ; ThrombHaemost, pp.302-314, 2012. ,
Update on the safety and bioequivalence of biosimilars-focus on enoxaparin ; Drug, Healthcare and Patient Safety, pp.133-141, 2013. ,
Biosimilars : an overview ; IJPSR, pp.2132-2144, 2013. ,
Recurrent Life-Threatening Deep Tissue Hematomas After Switching to Generic Enoxaparin: A Report and Perspective on the Approval Process for Biological Compounds, Clinical and Applied Thrombosis/Hemostasis, vol.59, issue.1, pp.104-110, 2012. ,
DOI : 10.1177/1076029611416641
Biosimilars : Current Scientific and Regulatory Considerations, Current Clinical Pharmacology, vol.2014, issue.9, pp.53-63 ,
The protein science of biosimilars, Nephrology Dialysis Transplantation, vol.21, issue.Supplement 5, pp.4-8, 2006. ,
DOI : 10.1093/ndt/gfl474
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.6, pp.507-532, 2001. ,
DOI : 10.1023/A:1014414520282
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights, Kidney International, vol.81, issue.8, pp.727-732, 2012. ,
DOI : 10.1038/ki.2011.500
A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization, Pharmacological Reports, vol.66, issue.2, pp.239-242, 2014. ,
DOI : 10.1016/j.pharep.2013.09.005
The state of art in the development of biosimilars ; Clinical Pharmacology and therapeutics, pp.405-417, 2012. ,
The challenge of biosimilars ; Annals of oncology, pp.411-419, 2007. ,
Development trends for human monoclonal antibody therapeutics, Nature Reviews Drug Discovery, vol.25, issue.10, pp.767-774, 2010. ,
DOI : 10.1038/nrd3229
Demystified ...: Monoclonal antibodies, Molecular Pathology, vol.53, issue.3, pp.111-118, 2000. ,
DOI : 10.1136/mp.53.3.111
Biosimilar agents in oncology/haematology: from approval to practice, European Journal of Haematology, vol.449, issue.4, pp.277-288, 2011. ,
DOI : 10.1111/j.1600-0609.2010.01566.x
Considerations in the clinical development of biotech medicines ; Regulatory Rapporteur, pp.5-7, 2013. ,
Statistical considerations for confirmatory clinical trials for similar biotherapeutic products, Biologicals, vol.39, issue.5, pp.266-269, 2011. ,
DOI : 10.1016/j.biologicals.2011.06.006
Watier H ; Les anticorps monoclonaux : une avancée thérapeutique récente et majeure, Janvier-Février, vol.64, issue.1, pp.1-7, 2009. ,
DOI : 10.2515/therapie/2009008
ADME of biologics-What Have We Learned from Small Molecules ? The AAPS Journal, pp.410-419, 2012. ,
Biosimilars in dermatology : Starting with infliximab ; Actasdermosifiliogr, pp.104-175, 2013. ,
Biosimilars : How similar or dissimilar are they ?; Nephrology, pp.341-346, 2006. ,
Biosimilars : Opportunity or Cause of Concerns ?, J Phar PharmaceutSci, vol.10, issue.3, pp.405-410, 2007. ,
Effects of protein aggregates: An immunologic perspective, The AAPS Journal, vol.8, issue.3, p.59, 2006. ,
DOI : 10.1208/aapsj080359
Manufacturing of Biodrugs, BioDrugs, vol.8, issue.11, pp.217-218, 2009. ,
DOI : 10.2165/11317110-000000000-00000
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nature Biotechnology, vol.109, issue.5, pp.555-560, 2007. ,
DOI : 10.1038/nbt1303
Biosimilarstherapeuctics : what do we need to consider ?, Nephrology Dialysis Tranplantation, vol.2, issue.1, pp.27-36, 2009. ,
Bioequivalence and the immunogenicity of biopharmaceuticals, Nature Reviews Drug Discovery, vol.1, issue.6, pp.457-62, 2002. ,
DOI : 10.1038/nrd818
Follow-on biologics: challenges of the 'next generation', Nephrology Dialysis Transplantation, vol.20, issue.suppl_4, pp.31-36, 2005. ,
DOI : 10.1093/ndt/gfh1085
Factors influencing the immunogenicity of therapeutic proteins, Nephrology Dialysis Transplantation, vol.20, issue.suppl_6, pp.3-9, 2005. ,
DOI : 10.1093/ndt/gfh1092
Biosimilar epoetins, Eur J Hosp Pharm, vol.3, pp.8-12, 2004. ,
DOI : 10.1007/978-3-7643-8698-6_7
Bioequivalence of HX 575 (recombinant human epoietin alpha) and a comparator epoietin alpha after Page 185 ,
Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial, BMC Clinical Pharmacology, vol.18, issue.2, p.10, 2009. ,
DOI : 10.1093/ndt/18.2.353
Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration, Pharmaceutical Research, vol.07, issue.2, pp.167-176, 1990. ,
DOI : 10.1023/A:1015880819328
Regulatory considerations for development of bioanalytical assays for biotechnology products, Bioanalysis, vol.3, issue.6, pp.597-603, 2011. ,
DOI : 10.4155/bio.11.27
Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology, J PharmSci, vol.99, pp.1028-1045, 2010. ,
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges, World Journal of Biological Chemistry, vol.3, issue.4, pp.73-92, 2012. ,
DOI : 10.4331/wjbc.v3.i4.73
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial, Annals of Hematology, vol.19, issue.Suppl 1, pp.971-978, 2010. ,
DOI : 10.1007/s00277-010-0973-6
URL : https://hal.archives-ouvertes.fr/hal-00549425
Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials, The Journal of Clinical Pharmacology, vol.56, issue.4, pp.1012-1036, 2009. ,
DOI : 10.1177/0091270009337512
Anti-Drug Antibodies ; Drugs and Therapy Studies, pp.56-63, 2012. ,
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?, British Journal of Clinical Pharmacology, vol.365, issue.1, pp.7-14 ,
DOI : 10.1111/j.1365-2125.2012.04323.x
Biosimilars: what clinicians should know, Blood, vol.120, issue.26, pp.5111-5116, 2012. ,
DOI : 10.1182/blood-2012-04-425744
Clinical Pharmacology considerations in biologics development ; ActapharmacologicaSinica ; September2012, pp.1339-1347 ,
Fixed Dosing Versus Body Size-Based Dosing of Therapeutic Peptides and Proteins in Adults, The Journal of Clinical Pharmacology, vol.45, issue.1, pp.18-28, 2012. ,
DOI : 10.1177/0091270010388648